AEB1102

DRUG2 trials

Sponsors

Aeglea Biotherapeutics

Conditions

Arginase I DeficiencyHyperargininemia

Phase 1

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

CompletedNCT02488044

Aeglea BiotherapeuticsArginase I Deficiency, Hyperargininemia

Start: 2016-06-30End: 2019-02-28Updated: 2019-06-12

Phase 2

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

CompletedNCT03378531

Aeglea BiotherapeuticsArginase I Deficiency, Hyperargininemia

Start: 2017-12-07End: 2022-12-15Updated: 2023-07-27